Investor Presentaiton
Continued Strong Pipeline Execution
2023 Key Milestones
Early Stage:
Opdivo
Neo-adjuvant NSCLC Ph3
(CM-816) approval in EU
iberdomide
(+/- Yervoy)
Initiation of pivotal
post-transplant
maintenance H2H vs
Revlimid
2024/2025 Key Milestones
Metastatic:
1L HCC Ph3 (CM-9DW) Reblozyl
1L+ MSI High CRC Ph3
(CM-8HW)
1L MF Ph3
(INDEPENDENCE)
EoE Ph3
cendakimab
Metastatic:
Early Stage:
Sotyktu
PSA Ph3
X 1L mCRPC Ph3 (CM-7DX)
Reblozyl
1L MDS (COMMANDS)
U.S. filing
Opdualag
1L NSCLC Ph21
Opdivo
(+/- Yervoy)
Peri-adj NSCLC Ph3
(CM-77T)
Zeposia
☐ Peri-adj MIBC Ph3
CD maintenance Ph3
(YELLOWSTONE)
ROS1+ NSCLC (TRIDENT-1)
Mod-to-severe PsO
(CM-078)
repotrectinib
U.S. filing
EU approval
Sotyktu
X
CD Ph2 (IM011-023)
3-5L MM Ph3 (KarMMa-3)
× UC Ph2 (IM011-127)
filing
Abecma
Initiation NDMM Ph3
LPA₁
(KarMMa-9)
Antagonist
Initiation IPF Ph3
PPF Ph2 (IM027-040)
2L TE LBCL EU approval
3L+ CLL Ph1/2
Opdualag
Camzyos
OHCM EU approval
Breyanzi
(TRANSCEND-CLL)
3L+FL Ph2 (TRANSCEND-
FL)
LIBREXIA
(milvexian)
Initiation Ph3
program²
alnuctamab
BCMA TCE
Adj HCC Ph3 (CM-9DX)
Stage III Unresectable
NSCLC Ph3 (CM-73L)
☐ Adj NSCLC Ph3
(ANVIL, co-op group)
1L HCC Ph2
X 2L+ HCC Ph2
2L/3L+ MSS mCRC Ph3
Initiation MM Ph3
ll Bristol Myers Squibb Q3 2023 Results
1. Data readout anticipated early 2024
2. ACS, SSP, AF trials conducted by Janssen
Milestones represent data readouts unless otherwise specified;
subject to positive registrational trials and health authority approval
Not for Product Promotional Use
10View entire presentation